Background
swapnil hiremath
The KDIGO CKD 2024 Guidelines Part 1: ...

This week, we will discuss the 2024 KDIGO Guidelines on CKD, part 1. In this section we will discuss the first two chapters on CKD evaluation and risk stratification. Let’s dive in!

The KDIGO CKD 2024 Guidelines Part 1: Evaluation and Risk Stratification
Background
Jade Teakell
Shedding Light on the Dense Matter of C3 ...

This week, we will discuss the role of ApoE in determining the subtypes of C3 Glomerulopathy.

Shedding Light on the Dense Matter of C3 Glomerulopathy
Background
swapnil hiremath
Healing, Hype, or Harm: The NefIgArd trial

This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?

Healing, Hype, or Harm: The NefIgArd trial
Background
Cristina Adriana Popa
PRAECISely Predicting Preeclampsia

This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.

PRAECISely Predicting Preeclampsia
Background
swapnil hiremath
The Worldwide Shadow of Kidney Disease

This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.

The Worldwide Shadow of Kidney Disease

NSAID Saftey

PRECISION Trial: The Visual Abstract

Here is our second attempt to putting together a visual abstract. Went horizontal instead of vertical this time. Still feeling out this new medium.

And here is the animated GIF

I think GIFCreator is the best online GIF creator. Tried a few of them. This was the best and gave me the most control.

When looking for the NEJM logo in google image search I came across this page. Breaks my heart. We miss you Alex.